Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)
Introduction
There is a need for new therapeutic approaches to the treatment of malignant pleural mesothelioma (MPM) due to its increasing incidence and limited treatment options. Few patients are suitable for radical surgery.2 Palliative surgery may be of some value but its true role needs to be defined in controlled trials.3 Radiotherapy can control some symptoms but has a limited role.4, 5 Chemotherapy is an effective palliative treatment for patients with MPM. A cisplatin combination is superior to cisplatin alone,6, 7 with response rate (RR) of 10–20% and 20–40% for single agent and combinations, respectively. The anti-folate pemetrexed was the first licensed drug in combination with cisplatin for MPM and this regimen is now considered the standard of care for this disease in patients with performance status 0 or 1. Unfortunately, less than a half of patients respond to this regimen and the median progression free survival is only 5.7 months.
The biological mechanisms of carcinogenesis of MPM remain unknown. Several mechanisms have been suggested including activation of the nuclear factor-kappaB (NF-κB) pathway via phosphoinositide 3-kinase (PI3K), and mutational loss of NF2. NF-κB is thought to be activated in mesothelioma by chronic inflammation and real or functional loss of the NF2 gene. Bortezomib is a small molecule proteasome 20S inhibitor developed as a novel agent to treat human malignancies.8 By inhibiting the single proteasome molecular target, bortezomib affects multiple signalling pathways. The antineoplastic effect includes inhibition of cell growth and survival pathways, induction of apoptosis, and inhibition of expression of genes that control cellular adhesion, migration and angiogenesis. Bortezomib also induces mitochondrial apoptosis in cells by a mechanism involving the B cell lymphoma 2 (BCL-2) family.9
In mesothelioma cell line treatment with bortezomib induced cell arrest in G2M phase, while it increased expression of cyclin-dependent kinase inhibitor p21 and the pro-apoptotic protein Bax.10 Pre-treatment of mesothelioma cells with bortezomib showed synergistic effect in combination with cisplatin.10 Bortezomib also decreases the activity of NF-κB and has demonstrated both in vitro and in vivo antitumour activity in mesothelioma cell lines.11 Bortezomib, however, exhibited limited activity as a single agent in the second line treatment of patients with MPM (response rate 5%).12
Adoption of uni-dimensional measurement standards as outlined by the Response Evaluation Criteria in Solid Tumours (RECIST) guidelines should make tumour response in MPM studies more meaningful.13 Byrne et al. described a similar method of response evaluation using uni-dimensional measurement of the tumour at three separate levels on cross-sectional computed tomography (CT) scan.14
Several phase II studies in MPM have been conducted by the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group. A pooled analysis of these studies1 suggested that progression free survival rate at 18 weeks (PFSR-18) was a meaningful parameter in the monitoring of new drug activity in mesothelioma1 and therefore was chosen as the primary end-point in this study.
The aim of the study was to establish whether cisplatin and bortezomib (CB) exhibit significant efficacy in chemo naïve patients with MPM on the basis of PFSR-18. In addition, this study was also intended to validate PFSR-18 as an end-point for phase II studies in MPM.
Section snippets
Materials and methods
This was a single arm phase II study in patients with histologically proven MPM (including mixed and sarcomatoid subtypes), recurrent/not suitable for radical surgery. Patients were: age ⩾18 years, World Health Organisation (WHO) performance status (PS) 0–1, life expectancy >12 weeks and appropriate cardiac function. Measurable or evaluable disease according to modified RECIST was required and patients had, adequate haematological (absolute neutrophil count (ANC) count >1.5 × 109/L, platelets >100 ×
Results
Patient flow and CONSORT diagram are shown in Fig. 1. From February 2007 to April 2010 a total of 82 patients were registered for this study. When 37 patients were accrued, the interim analysis showed that 19/37 reached the primary end-point. Therefore the study continued to accrue the full sample size. One patient was ineligible due to the presence of a malignant melanoma that had recurred within the previous 5 years.
The baseline patient- and disease-related characteristics of the study
Discussion
In this large single arm phase II study of CB in patients with MPM, the primary end-point was PFSR-18, defined as patients who were alive and progression free at 18 ± 1 weeks after registration. The PFSR-18 was 53% (42–55) and therefore did not meet the criteria for activity at a level that could predict success in a phase III study over current day standards as the lower boundary of the confidence interval was below the preset p0 of 50%.
The study was designed to give a definitive answer to the
Conflict of interest statement
None declared.
Acknowledgements
This publication was supported by educational grants from Johnson & Johnson Ltd. and by a donation from the ‘Cancer Research UK’ from the ‘United-Kingdom’ through the EORTC Charitable Trust.
M.O.B. wishes to acknowledge NHS funding through the NIHR biomedical research centre.
The authors thank all participating academic institutions of the EORTC LCG: National Cancer Institute Cairo, Royal Marsden Hospital, Universita Genova, Western General Hospital, Churchill Oxford, KOPA Golnik, University
References (18)
- et al.
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
Lancet Oncol
(2011) - et al.
Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma
J Thorac Oncol
(2012) - et al.
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma
Eur J Cancer
(2011) - et al.
Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma
J Thorac Oncol
(2012) - et al.
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
Ann Oncol
(2004) - et al.
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma – the EORTC Lung Cancer Group
J Clin Oncol
(2006) - et al.
Malignant pleural mesothelioma: when is radiation therapy indicated?
Expert Rev Anticanc
(2011) - et al.
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
J Clin Oncol
(2003) - et al.
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
J Clin Oncol
(2005)
Cited by (41)
Emerging therapies in malignant pleural mesothelioma
2019, Critical Reviews in Oncology/HematologyCitation Excerpt :O’Brien et al performed a single arm phase II trial to evaluate a first-line combination of cisplatin plus bortezomib, a proteasome inhibitor used in multiple myeloma patients. However, the authors showed a PFS rate at 18 weeks of 53%, which did not meet the criteria for activity to predict success in a phase III trial (O’Brien et al., 2013). Additionally, it was demonstrated that 60% of MPM patients do not express argininosuccinate synthetase 1 (ASS1), resulting in arginine depletion.
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
2016, Critical Reviews in Oncology/HematologyCitation Excerpt :The overall survival (OS) was 13.5 months (95% CI 10.5–15) with 56% (95% CI 44–66%) alive at 1 year. The median PFS was 5.1 months (95% CI 3.3–6.5) and the response rate was 28.4% (95% CI 18.9–39.5%) (O'Brien et al., 2013). Results from ongoing confirmatory studies are eagerly awaited
Treatment of malignant pleural mesothelioma: a 2016 update
2016, Revue des Maladies Respiratoires ActualitesMolecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors
2016, Taiwanese Journal of Obstetrics and GynecologyCitation Excerpt :A survival benefit has been reported in patients with nonsmall-cell lung carcinomas [21–23]. However, a poor clinical response has been observed in malignant pleural mesothelioma [24], metastatic esophageal cancer [25], and metastatic melanoma [26]. The addition of bortezomib to liposomal doxorubicin allowed the achievement of a partial response in 24% of platinum-sensitive patients with ovarian cancer, although no response was observed in chemoresistant patients [27].
Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy
2023, Journal of Experimental and Clinical Cancer Research
ClinicalTrials.gov Identifier: NCT00458913.